People who are weighing a new depression treatment ask us about the FDA more than almost anything else. Is it approved? Does that matter? What if it is not? Here are short, direct answers to the questions we hear most, grounded in a survey we commissioned this summer and in publicly available facts about each treatment.

None of this is medical advice. Deciding on any treatment is work for you and a clinician familiar with your background.

Do most people actually care about FDA approval?

Yes. Our poll covered 443 working-age people from a ten-state Midwest footprint and asked how much FDA approval would count toward trying an unfamiliar depression treatment. The answers: deciding for 19 percent, big for 40 percent, some for 27 percent, none for 14 percent. Add the top two and 59 percent give approval heavy weight. Every figure here has been validated and is final.

Then why do so few people pick it as a top priority?

Good catch. Allowed only two picks for what counts in a provider, respondents gave FDA approval just 27 percent, next to 85 percent for insurance and 43 percent for nearness to home. Our best reading is that people expect approval as a baseline, then compare providers on cost and convenience. It is a filter, not a tiebreaker.

Which depression treatments are FDA-approved?

Ordinary antidepressants carry depression approvals. So does Spravato, the esketamine brand, though its approval is specifically for treatment-resistant depression, which is depression that two or more antidepressant attempts have not adequately relieved. Other options have different regulatory standing, as described below.

Is ketamine FDA-approved for depression?

Not generic ketamine. It is FDA-approved as an anesthetic. When a clinic gives IV ketamine infusions for depression, that is off-label use. At-home ketamine, often prescribed through telehealth, is also off-label and sometimes involves compounded products. Of the ketamine family, only esketamine has approval for any kind of depression.

What about TMS?

TMS (transcranial magnetic stimulation) works through a coil placed on the scalp, with no medication involved. Because it is a device, it goes through the FDA's device pathway and is described as "cleared" rather than "approved." Its clearance applies to grown patients whose major depression persisted through antidepressant treatment.

Is "cleared" worse than "approved"?

It is different, not worse. Drugs and devices go through different FDA review processes, and each uses its own term. A TMS clinic that says "FDA-cleared" is using the accurate word.

Does FDA approval mean a treatment is safe for me?

It means the FDA found that, for the population studied, the benefits outweighed the risks when used as labeled. Risks remain, and approval says nothing about how the treatment fits your own health history. That is a question only a clinician can answer.

Why can't I just pick up Spravato at a pharmacy?

Because a safety program was a condition of its approval. Only certified sites may offer Spravato. Patients use the spray themselves while staff watch, are kept on site for a two-hour observation window at least, and leave the driving until the next day. Brain Recovery Centers has a page on what those supervised Spravato sessions are like. These requirements exist because of risks such as sedation, dissociation, and potential misuse. They are part of the approval, not a workaround.

If my doctor suggests an off-label treatment, should I be worried?

Not automatically. Off-label prescribing is legal and common, and sometimes the evidence behind it is solid. It is reasonable to ask what the evidence is, why your doctor prefers it for you, and whether there is an approved alternative.

Does FDA approval mean my insurance will pay?

Not necessarily. Approval makes coverage more likely for the labeled use, but most plans still require prior authorization for newer depression treatments. Coverage clearly matters to people: for 65 percent of our respondents, it would weigh big or decisively on trying anything at all. Given a choice of more insurance hoops or a faster self-pay start, half chose the insurance route.

How many people have heard of the approved esketamine product?

Very few. In our poll, 73 percent had never met the name Spravato and 21 percent recognized it without knowing more, leaving 6 percent able to explain it. Such thin awareness is one reason approved and unapproved ketamine options get confused.

How can I check a treatment's status myself?

For drugs, the FDA's public Drugs@FDA database lets you look up a product and read its official label, including what it is approved to treat. For devices, the FDA's device databases show clearance records. For esketamine, the manufacturer lists certified treatment centers. You can also ask the clinic directly, in writing, what product it uses and what that product is approved or cleared for.

Who should I talk to about this?

Your own doctor is a sensible first stop, and most people agree. Among our respondents, 74 percent named their doctor's endorsement as the strongest push toward something new, and 56 percent would begin with primary care. Ads, by contrast, moved just 2 percent.

I've never heard of any of this. Is that normal?

Completely. The 319 respondents who described their likely Google search wrote about feelings, not products, with entries such as "depressed" and "best ways to handle depression." Treatment names almost never came up, and no one needs that vocabulary before asking for help.

What if things feel urgent tonight?

Thoughts of suicide call for a person, not an FAQ. Put the reading aside and use 988 by voice or text; there is no charge, and the Suicide and Crisis Lifeline covers every state around the clock.

Methodology

The source is Pollfish survey 395586438. Its consumer panel supplied 443 respondents, adults 18 to 64 from Oklahoma, Illinois, Nebraska, Kansas, Wisconsin, Iowa, Indiana, Minnesota, Ohio and Missouri, and fieldwork finished June 23, 2026. A consent screener opened the questionnaire. Percentages on multi-select items use all respondents as the base. All figures come from the final validated file. Commissioning and payment were the publisher's.

FDA approval and depression treatment: your questions answered